Peptide Companion
Back to catalog
Peptide Companion
single
Weight Management
Vial: 30 mg

Tirzepatide (30 mg Vial)

Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists.

Detailed protocol below.

Dosing Schedule
PhaseWeekly Dose (mg)Units (per injection) (mL)
Weeks 1–42.5 mg25 units (0.25 mL) × 1 injection
Weeks 5–85 mg50 units (0.50 mL) × 1 injection
Weeks 9–127.5 mg75 units (0.75 mL) × 1 injection
Weeks 13–1610 mg100 units (1.0 mL) × 1 injection
Supplies Needed
  • •Peptide Vials (Tirzepatide, 30 mg each):
  • •Insulin Syringes (U‑100, 1 mL):
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.
References

  • StatPearls (NCBI Bookshelf)

    Farzam K, Patel P. Tirzepatide. StatPearls Publishing; 2024. Comprehensive overview of pharmacology, dosing, and clinical use.

    View source

  • Frontiers in Endocrinology

    Gallwitz B. GIP/GLP-1 receptor agonist Tirzepatide for type 2 diabetes and obesity. Front Endocrinol. 2022;13:1004044.

    View source

  • The Lancet

    Frias JP, et al. Efficacy and safety of LY3298176 (Tirzepatide), a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes (Phase 2 trial). Lancet. 2018;392(10160):2180-2193.

    View source

  • New England Journal of Medicine

    Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.

    View source

  • FDA Prescribing Information

    Mounjaro (Tirzepatide) injection Prescribing Information. Eli Lilly and Company; 2022.

    View source

  • CDC Injection Safety

    Preventing Unsafe Injection Practices. Guidelines for multi-dose vials and safe needle disposal.

    View source

  • MedlinePlus Medical Encyclopedia

    Subcutaneous (SQ) injections: Technique, site rotation, and best practices.

    View source

  • Mayo Clinic

    Tirzepatide (Subcutaneous route) – Drugs and Supplements. Clinical overview and patient information.

    View source

  • CDC Vaccine Administration

    Subcutaneous injection technique: angle, site selection, and no aspiration guidance.

    View source

  • Hospital Pharmacy (PubMed)

    Jordan MA, et al. Accurate measurement of small-volume parenterals with syringes. Hosp Pharm. 2021;56(3):165-171.

    View source

  • NCBI Bookshelf

    Best practices for injection: asepsis, preparation, and administration techniques.

    View source

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route for drug delivery.

    View source

Educational content adapted from peptidedosages.com. Not medical advice.